Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $2.20, provides guidance

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $8.13, $2.20 better than the analyst estimate of $5.93. Revenue for the quarter came in at $1.13 billion versus the consensus estimate of $1.11 billion.

GUIDANCE:

Jazz Pharmaceuticals sees Q4 2025 revenue of $4.175-4.275 billion, versus the consensus of $4.221 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
• Contango Silver & Gold starts drilling at Lucky Shot, updates on key projects
• VisionWave unveils two autonomous drone platforms at Eurosatory 2026